The engineering of an orally active conotoxin for the treatment of neuropathic pain.

From killers to curers: Peptides from cone snail venoms are potential therapeutic agents for the treatment of neuropathic pain. Unfortunately, these peptides suffer from the disadvantage of short biological half-lives and poor activity when taken orally. A new orally active conotoxin was developed to solve these problems.

[1]  K. Gayler,et al.  Drugs from the sea: conopeptides as potential therapeutics. , 2004, Current medicinal chemistry.

[2]  Stephen B. H. Kent,et al.  In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. , 2009 .

[3]  Alison Haythornthwaite,et al.  Analgesic α-Conotoxins Vc1.1 and Rg1A Inhibit N-Type Calcium Channels in Rat Sensory Neurons via GABAB Receptor Activation , 2008, The Journal of Neuroscience.

[4]  D. Craik,et al.  Are α9α10 Nicotinic Acetylcholine Receptors a Pain Target for α-Conotoxins? , 2007, Molecular Pharmacology.

[5]  C. Blackstone,et al.  Emerging themes of ER organization in the development and maintenance of axons , 2010, Current Opinion in Neurobiology.

[6]  David John Adams,et al.  Analgesic α-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in sensory neurons of α9 nicotinic receptor knockout mice , 2010, Channels.

[7]  Joav Merrick,et al.  Neurological Disorders: Public Health Challenges , 2007 .

[8]  R. Lewis,et al.  Oral absorption and in vivo biodistribution of α-conotoxin MII and a lipidic analogue , 2007 .

[9]  Gary J. Bennett,et al.  A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man , 1988, Pain.

[10]  Michelle L Colgrave,et al.  Cyclic MrIA: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter. , 2006, Journal of medicinal chemistry.

[11]  J. McIntosh,et al.  Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors , 2006, Proceedings of the National Academy of Sciences.

[12]  D. Craik,et al.  The Synthesis, Structural Characterization, and Receptor Specificity of the α-Conotoxin Vc1.1* , 2006, Journal of Biological Chemistry.

[13]  David J. Craik,et al.  Structure-activity relationships of alpha-conotoxins targeting neuronal nicotinic acetylcholine receptors. , 2004, European journal of biochemistry.

[14]  D. Craik,et al.  α-Selenoconotoxins, a New Class of Potent α7 Neuronal Nicotinic Receptor Antagonists* , 2006, Journal of Biological Chemistry.

[15]  A. Braun.  Coordinate regulation of stretch-activated channels and myogenic tone by polycystins 1 and 2 , 2010, Channels.

[16]  Norelle L Daly,et al.  Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Kracun,et al.  Effects of Quinine, Quinidine, and Chloroquine on α9α10 Nicotinic Cholinergic Receptors , 2005, Molecular Pharmacology.

[18]  J. McIntosh,et al.  Targeting the α9α10 nicotinic acetylcholine receptor to treat severe pain , 2007 .

[19]  K. Gayler,et al.  Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones , 2005, Brain Research.

[20]  D. Craik,et al.  Crystal structure at 1.1 A resolution of alpha-conotoxin PnIB: comparison with alpha-conotoxins PnIA and GI. , 1997, Biochemistry.

[21]  J. Farrar,et al.  Pharmacologic management of neuropathic pain: Evidence-based recommendations , 2007, PAIN.

[22]  D. Keays,et al.  A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. , 2003, Biochemistry.

[23]  R. Lewis.  Conotoxins: molecular and therapeutic targets. , 2009, Progress in molecular and subcellular biology.

[24]  De-Pei Li,et al.  Modulation of pain transmission by G-protein-coupled receptors. , 2008, Pharmacology & therapeutics.

[25]  B. Olivera,et al.  Conus venoms: a rich source of novel ion channel-targeted peptides. , 2004, Physiological reviews.